为了更好地治疗Mycobacterium的肺部疾病
Véronique Dartois1,2, Thomas Dick1,2,3
1Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Clinical microbiology reviews
|October 3, 2024
概括
菌根 (Mab) 肺部感染由于病原体耐药性和无效药物而缺乏批准的治疗方法. 新的战略重点是口服抗生素,组合药物和优化药物开发,以提高治愈率.
科学领域:
- 传染性疾病 传染性疾病
- 抗微生物耐药性 抗微生物耐药性
- 肺部医学 肺部医学
背景情况:
- 菌根杆菌 (Mab) 导致严重的肺部感染,治疗选择有限.
- 马布感染与结核病有相似之处,但结果较差,治疗方法较少.
- 目前对马布病的治疗方法通常是无效的,有毒的,并通过肠道给药.
研究的目的:
- 确定导致Mab疾病治愈率低下的因素.
- 提出临床前策略,开发安全,绝育和无注射药物的Mab治疗方案.
- 突出Mab药物发现和临床开发中的知识和工具缺口.
主要方法:
- 讨论马布的内在耐药性和病原体持久性.
- 建议优先考虑口服杀菌抗生素和早期药物组合测试.
- 重点是优化新药的潜在药物,并考虑肺部特定的药理动力学和药理动力学标.
主要成果:
- 确定内在耐药性和持久性是马布治疗的关键挑战.
- 提出了多方面的临床前策略,包括口服药物和组合疗法.
- 强调了对改善的临床前模型和转化工具的需要,以便为Mab药物发现.
结论:
- 迫切需要新,安全和有效的治疗方案来治疗Mycobacterium的肺部感染.
- 开发需要优先考虑口服杀菌剂,组合策略和优化药物发现管道.
- 学术界,工业界和政府之间的协作努力对于推进Mab疗法至关重要.
相关概念视频
Cystic Fibrosis: Management
657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
657
Pneumonia IV: Management
1.2K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K
Pulmonary Tuberculosis I
1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Pulmonary Tuberculosis III
1.8K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.8K
Pulmonary Tuberculosis IV
828
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
828
Pulmonary Tuberculosis V
1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K


